\-\ Texto\\:\\ \ \(0\)\
\-\ normal\\ physical\\ exam\\.\\ urinalysis\\ was\\ consistent\\ with\\ gross\\ hematuria\\,\\ no\\ crystals\\ were\\ visualized\\,\\ wbc\\'s\\ were\\ within\\ normal\\ limits\\.\ \(0\)\
\-\ transurethral\\ resection\\ of\\ bladder\\ tumor\\,\\ turbt\\,\\ with\\ biopsy\\ of\\ remaining\\ bladder\\ and\\ prostatic\\ urethra\\ is\\ normally\\ sufficient\\ for\\ low\\-grade\\ urothelial\\ cancer\\.\\ adjuvant\\ intravesicular\\ therapy\\ may\\ be\\ included\\ for\\ cases\\ of\\ high\\-grade\\ urothelial\\ cancer\\.\\ bcg\\ is\\ most\\ commonly\\ used\\ due\\ to\\ its\\ favorable\\ toxicity\\ profile\\ and\\ its\\ efficacy\\.\\ six\\ months\\ of\\ bcg\\ therapy\\ is\\ usually\\ required\\ to\\ qualify\\ as\\ bcg\\ resistant\\ tumors\\.\\ alternatives\\ for\\ these\\ tumors\\ include\\ adding\\ mitomycin\\ c\\,\\ anthracyclines\\,\\ and\\ interferon\\.\ \(0\)\
\-\ high\\ grade\\ tumors\\ are\\ most\\ likely\\ to\\ be\\ muscle\\-invasive\\.\\ mvac\\ is\\ considered\\ first\\ line\\ multi\\-agent\\ chemotherapy\\.\ \(0\)\
\-\ follow\\-up\\ includes\\ screening\\ cystography\\ for\\ recurrence\\ of\\ disease\\ which\\ is\\ not\\ uncommon\\.\ \(0\)\
\-\ bilateral\\ extrarenal\\ pelves\\.\ \(0\)\
\-\ no\\ evidence\\ of\\ obstructing\\ stones\\ or\\ stones\\ in\\ the\\ bladder\\.\\ \\ \ \(0\)\
\-\ abnormal\\ layering\\ of\\ contrast\\ material\\ within\\ the\\ posterior\\ aspect\\ of\\ the\\ bladder\\ concerning\\ for\\ clot\\ vs\\ mural\\ mass\\.\ \(0\)\
\-\ metastatic\\ disease\\ with\\ spread\\ to\\ bilateral\\ hilar\\ and\\ mediastinal\\ lymph\\ nodes\\.\ \(0\)\
\-\ metastatic\\ disease\\ with\\ spread\\ to\\ left\\ lower\\ lung\\ lobe\\.\ \(0\)\
\-\ urothelial\\ cancer\ \(3\)\
\-\ bladder\\ cancer\\ \\-\\ mainly\\ urothelial\\ \\(transitional\\ cell\\)\\ cancer\ \(0\)\
\-\ bph\ \(3\)\
\-\ renal\\ stones\ \(7\)\
\-\ cystitis\ \(180\)\
\-\ 82\\ yo\\ man\\ with\\ 2\\-month\\ history\\ of\\ painless\\ gross\\ hematuria\ \(1\)\
\-\ this\\ man\\ had\\ metastasis\\ to\\ his\\ right\\ acetabulum\\ and\\ right\\ femur\\,\\ right\\ lower\\ lung\\,\\ and\\ caudate\\ lobe\\ of\\ the\\ liver\\,\\ with\\ large\\ infiltration\\ of\\ mediastinal\\ and\\ perihilar\\ lymph\\ nodes\\.\\ up\\ to\\ 45\\%\\ of\\ new\\ urothelial\\ cancers\\ are\\ high\\ grade\\ and\\ half\\ of\\ those\\ are\\ already\\ invasive\\.\\ metastases\\ most\\ commonly\\ travel\\ to\\ lung\\ and\\ liver\\.\ \(0\)\
\-\ this\\ patient\\'s\\ initial\\ non\\-contrast\\ ct\\ \\ did\\ not\\ clearly\\ show\\ the\\ mural\\ mass\\ as\\ it\\ is\\ shown\\ here\\.\\ his\\ enlarged\\ prostate\\ produced\\ a\\ mass\\ effect\\ indenting\\ the\\ contour\\ of\\ the\\ posterior\\ bladder\\ wall\\.\\ this\\ highlights\\ the\\ need\\ for\\ careful\\ evaluation\\ of\\ the\\ bladder\\ wall\\ when\\ it\\ is\\ opposed\\ by\\ the\\ prostate\\ and\\ having\\ a\\ properly\\ distended\\ bladder\\ to\\ evaluate\\ thickening\\ of\\ the\\ trabeculated\\ bladder\\ wall\\.\ \(0\)\
\-\ this\\ patient\\'s\\ hilar\\ and\\ mediastinal\\ lymphadenopathy\\ with\\ mass\\ effect\\ on\\ the\\ pulmonary\\ vessels\\ aggravated\\ this\\ man\\'s\\ congestive\\ heart\\ failure\\ with\\ frequent\\ admissions\\ for\\ exacerbations\\ to\\ rule\\ out\\ pulmonary\\ embolisms\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ urothelial\\:\\ 0\\.08502523930773435\ \(0\)\
\-\ bladder\\:\\ 0\\.08150312803979443\ \(0\)\
\-\ bcg\\:\\ 0\\.05819235558365488\ \(0\)\
\-\ cancer\\:\\ 0\\.03667317577499694\ \(0\)\
\-\ stones\\:\\ 0\\.03443872963057363\ \(0\)\
\-\ \\-\\:\\ 0\\.028695484992820312\ \(0\)\
\-\ mediastinal\\:\\ 0\\.028418793353465345\ \(0\)\
\-\ mural\\:\\ 0\\.025400912299660943\ \(0\)\
\-\ tumors\\:\\ 0\\.02514138139167494\ \(0\)\
\-\ prostate\\:\\ 0\\.023701578615929208\ \(0\)\
\-\ turbt\\:\\ 0\\.023017019383724538\ \(0\)\
\-\ anthracyclines\\:\\ 0\\.023017019383724538\ \(0\)\
\-\ muscle\\-invasive\\:\\ 0\\.023017019383724538\ \(0\)\
\-\ mvac\\:\\ 0\\.023017019383724538\ \(0\)\
\-\ hilar\\:\\ 0\\.022421565780247822\ \(0\)\
\-\ spread\\:\\ 0\\.021584267346434875\ \(0\)\
\-\ gross\\:\\ 0\\.02125632530341122\ \(0\)\
\-\ multi\\-agent\\:\\ 0\\.02120723562247142\ \(0\)\
\-\ pelves\\:\\ 0\\.02120723562247142\ \(0\)\
\-\ embolisms\\:\\ 0\\.02120723562247142\ \(0\)\
\-\ hematuria\\:\\ 0\\.021166289760672283\ \(0\)\
\-\ nodes\\:\\ 0\\.020155046299557375\ \(0\)\
\-\ intravesicular\\:\\ 0\\.020148579987724253\ \(0\)\
\-\ qualify\\:\\ 0\\.020148579987724253\ \(0\)\
\-\ mitomycin\\:\\ 0\\.020148579987724253\ \(0\)\
\-\ admissions\\:\\ 0\\.020148579987724253\ \(0\)\
\-\ \\'s\\:\\ 0\\.019676727084773315\ \(0\)\
\-\ alternatives\\:\\ 0\\.019397451861218298\ \(0\)\
\-\ 2\\-month\\:\\ 0\\.019397451861218298\ \(0\)\
\-\ lung\\:\\ 0\\.01938766934912856\ \(0\)\
\-\ wall\\:\\ 0\\.01938766934912856\ \(0\)\
\-\ bph\\:\\ 0\\.018814831622799996\ \(0\)\
\-\ adding\\:\\ 0\\.01833879622647113\ \(0\)\
\-\ interferon\\:\\ 0\\.01833879622647113\ \(0\)\
\-\ cystography\\:\\ 0\\.01833879622647113\ \(0\)\
\-\ lymph\\:\\ 0\\.018013276286917214\ \(0\)\
\-\ transurethral\\:\\ 0\\.017936314033710665\ \(0\)\
\-\ extrarenal\\:\\ 0\\.017936314033710665\ \(0\)\
\-\ trabeculated\\:\\ 0\\.017936314033710665\ \(0\)\
\-\ indenting\\:\\ 0\\.017005047861546874\ \(0\)\
\-\ highlights\\:\\ 0\\.017005047861546874\ \(0\)\
\-\ exacerbations\\:\\ 0\\.017005047861546874\ \(0\)\
\-\ grade\\:\\ 0\\.016996536777811856\ \(0\)\
\-\ commonly\\:\\ 0\\.016838284300029458\ \(0\)\
\-\ its\\:\\ 0\\.016838284300029458\ \(0\)\
\-\ crystals\\:\\ 0\\.016126530272457546\ \(0\)\
\-\ prostatic\\:\\ 0\\.016126530272457546\ \(0\)\
\-\ aggravated\\:\\ 0\\.016126530272457546\ \(0\)\
\-\ man\\:\\ 0\\.01582975334013054\ \(0\)\
\-\ effect\\:\\ 0\\.015799259807150103\ \(0\)\
\-\ toxicity\\:\\ 0\\.01561959550890413\ \(0\)\
\-\ efficacy\\:\\ 0\\.01561959550890413\ \(0\)\
\-\ properly\\:\\ 0\\.015470356830470846\ \(0\)\
\-\ most\\:\\ 0\\.01545301677593793\ \(0\)\
\-\ liver\\:\\ 0\\.015384968724975058\ \(0\)\
\-\ cystitis\\:\\ 0\\.01532918915091399\ \(0\)\
\-\ travel\\:\\ 0\\.01532918915091399\ \(0\)\
\-\ high\\-grade\\:\\ 0\\.015195264100293752\ \(0\)\
\-\ perihilar\\:\\ 0\\.015195264100293752\ \(0\)\
\-\ resistant\\:\\ 0\\.015067874637710378\ \(0\)\
\-\ adjuvant\\:\\ 0\\.014946412455896037\ \(0\)\
\-\ caudate\\:\\ 0\\.014946412455896037\ \(0\)\
\-\ urethra\\:\\ 0\\.014510239911083592\ \(0\)\
\-\ favorable\\:\\ 0\\.014510239911083592\ \(0\)\
\-\ profile\\:\\ 0\\.014510239911083592\ \(0\)\
\-\ opposed\\:\\ 0\\.01441170119572368\ \(0\)\
\-\ mainly\\:\\ 0\\.014225124266266381\ \(0\)\
\-\ layering\\:\\ 0\\.014136608465546586\ \(0\)\
\-\ careful\\:\\ 0\\.013968100577458934\ \(0\)\
\-\ sufficient\\:\\ 0\\.01388775682114887\ \(0\)\
\-\ 82\\:\\ 0\\.01380981174765101\ \(0\)\
\-\ acetabulum\\:\\ 0\\.01380981174765101\ \(0\)\
\-\ congestive\\:\\ 0\\.01380981174765101\ \(0\)\
\-\ urinalysis\\:\\ 0\\.013734126272786121\ \(0\)\
\-\ low\\-grade\\:\\ 0\\.013660573069217724\ \(0\)\
\-\ transitional\\:\\ 0\\.013660573069217724\ \(0\)\
\-\ cancers\\:\\ 0\\.013451584276336429\ \(0\)\
\-\ obstructing\\:\\ 0\\.01338548033904063\ \(0\)\
\-\ for\\:\\ 0\\.01332573639816973\ \(0\)\
\-\ already\\:\\ 0\\.013258090876457258\ \(0\)\
\-\ pulmonary\\:\\ 0\\.013036816241358034\ \(0\)\
\-\ clot\\:\\ 0\\.013020566651377033\ \(0\)\
\-\ his\\:\\ 0\\.012861039308861264\ \(0\)\
\-\ produced\\:\\ 0\\.01260191743447056\ \(0\)\
\-\ this\\:\\ 0\\.012547483202534373\ \(0\)\
\-\ mass\\:\\ 0\\.012412125398930178\ \(0\)\
\-\ high\\:\\ 0\\.012211728778469011\ \(0\)\
\-\ infiltration\\:\\ 0\\.012158316816205812\ \(0\)\
\-\ lobe\\:\\ 0\\.012006920876885296\ \(0\)\
\-\ therapy\\:\\ 0\\.011930239144859599\ \(0\)\
\-\ half\\:\\ 0\\.011779251516350727\ \(0\)\
\-\ concerning\\:\\ 0\\.011709621628407748\ \(0\)\
\-\ here\\:\\ 0\\.011641800515083307\ \(0\)\
\-\ remaining\\:\\ 0\\.011608539351173569\ \(0\)\
\-\ clearly\\:\\ 0\\.011479576543524543\ \(0\)\
\-\ metastatic\\:\\ 0\\.011232947277368618\ \(0\)\
\-\ painless\\:\\ 0\\.011210782890123911\ \(0\)\
\-\ invasive\\:\\ 0\\.011210782890123911\ \(0\)\
\-\ frequent\\:\\ 0\\.01115463091826761\ \(0\)\
\-\ to\\:\\ 0\\.011150603353602774\ \(0\)\
\-\ need\\:\\ 0\\.011127001389989446\ \(0\)\
\-\ normally\\:\\ 0\\.010993076339369207\ \(0\)\
\-\ six\\:\\ 0\\.010967096363251275\ \(0\)\
\-\ disease\\:\\ 0\\.01094050293380447\ \(0\)\
\-\ uncommon\\:\\ 0\\.010915899310017917\ \(0\)\
\-\ non\\-contrast\\:\\ 0\\.010890672388577351\ \(0\)\
\-\ bilateral\\:\\ 0\\.010829335401119812\ \(0\)\
\-\ contour\\:\\ 0\\.010816421904711727\ \(0\)\
\-\ distended\\:\\ 0\\.010792133673217437\ \(0\)\
\-\ c\\:\\ 0\\.01060555674376014\ \(0\)\
\-\ 45\\:\\ 0\\.010308052150159048\ \(0\)\
\-\ included\\:\\ 0\\.010288044649517877\ \(0\)\
\-\ posterior\\:\\ 0\\.010285318792179888\ \(0\)\
\-\ is\\:\\ 0\\.010276854957423184\ \(0\)\
\-\ having\\:\\ 0\\.010248483800900116\ \(0\)\
\-\ those\\:\\ 0\\.010152127255376746\ \(0\)\
\-\ were\\:\\ 0\\.010132043533628832\ \(0\)\
\-\ lower\\:\\ 0\\.010035833260385705\ \(0\)\
\-\ it\\:\\ 0\\.010030539867013142\ \(0\)\
\-\ material\\:\\ 0\\.009969467755097607\ \(0\)\
\-\ recurrence\\:\\ 0\\.009733478038470272\ \(0\)\
\-\ femur\\:\\ 0\\.009638523353951016\ \(0\)\
\-\ metastases\\:\\ 0\\.009531938511861578\ \(0\)\
\-\ screening\\:\\ 0\\.009517061172136675\ \(0\)\
\-\ lymphadenopathy\\:\\ 0\\.009487558416904473\ \(0\)\
\-\ rule\\:\\ 0\\.009317217628736324\ \(0\)\
\-\ limits\\:\\ 0\\.009196380154678867\ \(0\)\
\-\ line\\:\\ 0\\.009170270276520686\ \(0\)\
\-\ are\\:\\ 0\\.009124338427124817\ \(0\)\
\-\ visualized\\:\\ 0\\.009031154436800224\ \(0\)\
\-\ evaluate\\:\\ 0\\.009018867515031522\ \(0\)\
\-\ considered\\:\\ 0\\.009006638143458607\ \(0\)\
\-\ includes\\:\\ 0\\.008994465785479988\ \(0\)\
\-\ vessels\\:\\ 0\\.008982349911964315\ \(0\)\
\-\ shown\\:\\ 0\\.008946336016057434\ \(0\)\
\-\ vs\\:\\ 0\\.008784543003657436\ \(0\)\
\-\ failure\\:\\ 0\\.008740099955173282\ \(0\)\
\-\ used\\:\\ 0\\.008559227563832799\ \(0\)\
\-\ within\\:\\ 0\\.00851243555292993\ \(0\)\
\-\ metastasis\\:\\ 0\\.00835182069530007\ \(0\)\
\-\ wbc\\:\\ 0\\.008133354701242329\ \(0\)\
\-\ did\\:\\ 0\\.008055923344629044\ \(0\)\
\-\ required\\:\\ 0\\.008030614913282674\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.00799724748078555\ \(0\)\
\-\ biopsy\\:\\ 0\\.007915648150487625\ \(0\)\
\-\ new\\:\\ 0\\.00777490333368292\ \(0\)\
\-\ heart\\:\\ 0\\.007752166185140403\ \(0\)\
\-\ enlarged\\:\\ 0\\.0076125876511331765\ \(0\)\
\-\ thickening\\:\\ 0\\.0075629884326197175\ \(0\)\
\-\ first\\:\\ 0\\.00748690191850092\ \(0\)\
\-\ cases\\:\\ 0\\.007432926537809746\ \(0\)\
\-\ initial\\:\\ 0\\.007393164864959029\ \(0\)\
\-\ out\\:\\ 0\\.007373508816862967\ \(0\)\
\-\ follow\\-up\\:\\ 0\\.007258582223085488\ \(0\)\
\-\ right\\:\\ 0\\.00706238936640013\ \(0\)\
\-\ aspect\\:\\ 0\\.007008595129199367\ \(0\)\
\-\ normal\\:\\ 0\\.006995365298167629\ \(0\)\
\-\ resection\\:\\ 0\\.0069580043225070986\ \(0\)\
\-\ be\\:\\ 0\\.006881236153232006\ \(0\)\
\-\ show\\:\\ 0\\.0068489711083332275\ \(0\)\
\-\ usually\\:\\ 0\\.006775269592341407\ \(0\)\
\-\ as\\:\\ 0\\.006749751989003279\ \(0\)\
\-\ yo\\:\\ 0\\.006713711549093373\ \(0\)\
\-\ renal\\:\\ 0\\.00670359151294535\ \(0\)\
\-\ evaluation\\:\\ 0\\.006481041242367644\ \(0\)\
\-\ not\\:\\ 0\\.006448139278025772\ \(0\)\
\-\ when\\:\\ 0\\.006389898792731085\ \(0\)\
\-\ abnormal\\:\\ 0\\.006363165118315695\ \(0\)\
\-\ \\,\\:\\ 0\\.006361333132260017\ \(0\)\
\-\ likely\\:\\ 0\\.006293185289649234\ \(0\)\
\-\ include\\:\\ 0\\.0062588863917239865\ \(0\)\
\-\ months\\:\\ 0\\.006093841500496259\ \(0\)\
\-\ cell\\:\\ 0\\.006026738150343307\ \(0\)\
\-\ up\\:\\ 0\\.005999600916590662\ \(0\)\
\-\ due\\:\\ 0\\.005953726247918642\ \(0\)\
\-\ evidence\\:\\ 0\\.005849719538816914\ \(0\)\
\-\ these\\:\\ 0\\.00580638300772282\ \(0\)\
\-\ physical\\:\\ 0\\.0054739040981233375\ \(0\)\
\-\ consistent\\:\\ 0\\.00547075266013369\ \(0\)\
\-\ \\%\\:\\ 0\\.00520449355965015\ \(0\)\
\-\ tumor\\:\\ 0\\.005201650918043894\ \(0\)\
\-\ and\\:\\ 0\\.005169971444006274\ \(0\)\
\-\ contrast\\:\\ 0\\.004994192393754322\ \(0\)\
\-\ exam\\:\\ 0\\.004901394099084956\ \(0\)\
\-\ may\\:\\ 0\\.004893807751692229\ \(0\)\
\-\ large\\:\\ 0\\.004878700866399686\ \(0\)\
\-\ of\\:\\ 0\\.0048669995111431195\ \(0\)\
\-\ had\\:\\ 0\\.004814229293056679\ \(0\)\
\-\ no\\:\\ 0\\.004493180943622987\ \(0\)\
\-\ patient\\:\\ 0\\.004473064913401503\ \(0\)\
\-\ the\\:\\ 0\\.00433157027792039\ \(0\)\
\-\ which\\:\\ 0\\.004164868374001433\ \(0\)\
\-\ by\\:\\ 0\\.003715067632493146\ \(0\)\
\-\ ct\\:\\ 0\\.0031208972673421485\ \(0\)\
\-\ history\\:\\ 0\\.003081500098451915\ \(0\)\
\-\ or\\:\\ 0\\.0026149419032994977\ \(0\)\
\-\ was\\:\\ 0\\.0025803590658320806\ \(0\)\
\-\ left\\:\\ 0\\.0024963584054123102\ \(0\)\
\-\ with\\:\\ 0\\.0024439514587966523\ \(0\)\
\-\ a\\:\\ 0\\.0020710172418725915\ \(0\)\
\-\ \\.\\:\\ 0\\.0020391378437117965\ \(0\)\
\-\ on\\:\\ 0\\.0018900548625729193\ \(0\)\
\-\ \\(\\:\\ 0\\.0018860619484173905\ \(0\)\
\-\ \\)\\:\\ 0\\.001863022694812807\ \(0\)\
\-\ in\\:\\ 0\\.0011002538645959658\ \(0\)\
